Print this page
 Email this page

 Connect with UMMC on:
 Twitter
 Facebook
 YouTube
iPhone

 Share this page:

Bookmark and Share

Home > Medical Reference > Encyclopedia (English)



 

Video details

[ Flash player icon ] Please install flash player to see this video.

Hospital Virtual Tour

Click to take a virtual tour

Related Content


 

U.S. Brand Names:

Avagard™ [OTC]; BactoShield® CHG [OTC]; Betasept® [OTC]; ChloraPrep® [OTC]; Chlorostat® [OTC]; Dyna-Hex® [OTC]; Hibiclens® [OTC]; Hibistat® [OTC]; Operand® Chlorhexidine Gluconate [OTC]; Peridex®; PerioChip®; PerioGard®

Synonyms:

CHG; 3M™ Avagard™ [OTC]

Generic Available:

Yes: Oral liquid

Canadian Brand Names:

Apo-Chlorhexadine®; Hibidil® 1:2000; ORO-Clense; SpectroGram 2™

Use:

Skin cleanser for surgical scrub, cleanser for skin wounds, preoperative skin preparation, germicidal hand rinse, and as antibacterial dental rinse. Chlorhexidine is active against gram-positive and gram-negative organisms, facultative anaerobes, aerobes, and yeast.

Orphan drug: Peridex®: Oral mucositis with cytoreductive therapy when used for patients undergoing bone marrow transplant

Use - Dental:

Antibacterial dental rinse; chlorhexidine is active against gram-positive and gram-negative organisms, facultative anaerobes, aerobes, and yeast

Chip, for periodontal pocket insertion: Indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis; may be used as part of a periodontal maintenance program

Pregnancy Risk Factor:

B

Contraindications:

Hypersensitivity to chlorhexidine gluconate or any component of the formulation

Warnings/Precautions:

Oral: Staining of oral surfaces (mucosa, teeth, tooth restorations, dorsum of tongue) may occur; may be visible as soon as 1 week after therapy begins and is more pronounced when there is a heavy accumulation of unremoved plaque and when teeth fillings have rough surfaces. Stain does not have a clinically adverse effect, but because removal may not be possible, patient with frontal restoration should be advised of the potential permanency of the stain.

Topical: For topical use only. Keep out of eyes and ears. May stain fabric. There have been case reports of anaphylaxis following chlorhexidine disinfection. Not for preoperative preparation of face or head; avoid contact with meninges.

Adverse Reactions:

Oral:

>10%: Increase of tartar on teeth, changes in taste. Staining of oral surfaces (mucosa, teeth, dorsum of tongue) may be visible as soon as 1 week after therapy begins and is more pronounced when there is a heavy accumulation of unremoved plaque and when teeth fillings have rough surfaces. Stain does not have a clinically adverse effect but because removal may not be possible, patient with frontal restoration should be advised of the potential permanency of the stain.

1% to 10%: Gastrointestinal: Tongue irritation, oral irritation

<1%: Facial edema, nasal congestion, dyspnea

Topical: Skin erythema and roughness, dryness, sensitization, allergic reactions

Overdosage/Toxicology:

Symptoms of oral overdose include gastric distress, nausea, or signs of ethanol intoxication

Drug Interactions:

No data reported

Stability:

Store at room temperature

Avagard™: Avoid excessive heat. Ethanol-containing products are flammable; keep away from flames or fire. Hand lotions and gel hand sanitizers are incompatible. The thickeners used in these products (eg, carbomer) react to form an insoluble salt and cause loss of antibacterial action.

Mechanism of Action:

The bactericidal effect of chlorhexidine is a result of the binding of this cationic molecule to negatively charged bacterial cell walls and extramicrobial complexes. At low concentrations, this causes an alteration of bacterial cell osmotic equilibrium and leakage of potassium and phosphorous resulting in a bacteriostatic effect. At high concentrations of chlorhexidine, the cytoplasmic contents of the bacterial cell precipitate and result in cell death.

Pharmacodynamics/Kinetics:

Topical hand sanitizer (Avagard™): Duration of antimicrobial protection: 6 hours

Oral rinse (Peridex®, PerioGard®):

Absorption: ~30% retained in the oral cavity following rinsing and slowly released into oral fluids; poorly absorbed

Time to peak, plasma: Oral rinse: Detectable levels not present after 12 hours

Excretion: Feces (~90%); urine (<1%)

Dosage:

Adults:

Oral rinse (Peridex®, PerioGard®):

Floss and brush teeth, completely rinse toothpaste from mouth and swish 15 mL (one capful) undiluted oral rinse around in mouth for 30 seconds, then expectorate. Caution patient not to swallow the medicine and instruct not to eat for 2-3 hours after treatment. (Cap on bottle measures 15 mL.)

Treatment of gingivitis: Oral prophylaxis: Swish for 30 seconds with 15 mL chlorhexidine, then expectorate; repeat twice daily (morning and evening). Patient should have a re-evaluation followed by a dental prophylaxis every 6 months.

Periodontal chip: One chip is inserted into a periodontal pocket with a probing pocket depth 5 mm. Up to 8 chips may be inserted in a single visit. Treatment is recommended every 3 months in pockets with a remaining depth 5 mm. If dislodgment occurs 7 days or more after placement, the subject is considered to have had the full course of treatment. If dislodgment occurs within 48 hours, a new chip should be inserted. The chip biodegrades completely and does not need to be removed. Patients should avoid dental floss at the site of PerioChip® insertion for 10 days after placement because flossing might dislodge the chip.

Insertion of periodontal chip: Pocket should be isolated and surrounding area dried prior to chip insertion. The chip should be grasped using forceps with the rounded edges away from the forceps. The chip should be inserted into the periodontal pocket to its maximum depth. It may be maneuvered into position using the tips of the forceps or a flat instrument.

Cleanser:

Surgical scrub: Scrub 3 minutes and rinse thoroughly, wash for an additional 3 minutes

Hand sanitizer (Avagard™): Dispense 1 pumpful in palm of one hand; dip fingertips of opposite hand into solution and work it under nails. Spread remainder evenly over hand and just above elbow, covering all surfaces. Repeat on other hand. Dispense another pumpful in each hand and reapply to each hand up to the wrist. Allow to dry before gloving.

Hand wash: Wash for 15 seconds and rinse

Hand rinse: Rub 15 seconds and rinse

Administration:

Hand sanitizer (Avagard™): To facilitate drying, continue rubbing hand prep into hands until dry.

Periodontal chip insertion: Pocket should be isolated and surrounding area dried prior to chip insertion. The chip should be grasped using forceps with the rounded edges away from the forceps. The chip should be inserted into the periodontal pocket to its maximum depth. It may be maneuvered into position using the tips of the forceps or a flat instrument. The chip biodegrades completely and does not need to be removed. Patients should avoid dental floss at the site of PerioChip® insertion for 10 days after placement because flossing might dislodge the chip.

Topical: Keep out of eyes, ears, and mouth. Do not routinely apply to wounds which involve more than superficial layers of skin.

Patient Education:

Oral rinse: Do not swallow, do not rinse after use; may cause reduced taste perception which is reversible; may cause discoloration of teeth

Periodontal chip: Avoid dental floss at the site of the chip insertion for 10 days after placement because flossing might dislodge the chip.

Topical: For external use only.

Nursing Implications:

Inform patient that reduced taste perception during treatment is reversible with discontinuation of chlorhexidine

Dental Health: Effects on Dental Treatment:

Key adverse event(s) related to dental treatment: Increased tartar on teeth, altered taste perception, staining of oral surfaces (mucosa, teeth, dorsum of tongue), and oral/tongue irritation. Staining may be visible as soon as 1 week after therapy begins and is more pronounced when there is a heavy accumulation of unremoved plaque and when teeth fillings have rough surfaces. Stain does not have a clinically adverse effect but because removal may not be possible, patient with frontal restoration should be advised of the potential permanency of the stain.

Dental Health: Vasoconstrictor/Local Anesthetic Precautions:

No information available to require special precautions

Mental Health: Effects on Mental Status:

None reported

Mental Health: Effects on Psychiatric Treatment:

None reported

Dosage Forms:

Chip, for periodontal pocket insertion (PerioChip®): 2.5 mg

Liquid, topical [surgical scrub]:

Avagard™: 1% (500 mL) [contains ethyl alcohol and moisturizers]

BactoShield® CHG: 2% (120 mL, 480 mL, 750 mL, 1000 mL, 3800 mL); 4% (120 mL, 480 mL, 750 mL, 1000 mL, 3800 mL) [contains isopropyl alcohol]

Betasept®: 4% (120 mL, 240 mL, 480 mL, 960 mL, 3840 mL) [contains isopropyl alcohol]

ChloraPrep®: 2% (0.67 mL, 1.5 mL, 3 mL, 10.5 mL) [contains isopropyl alcohol 70%; prefilled applicator]

Chlorostat®: 2% (360 mL, 3840 mL) [contains isopropyl alcohol]

Dyna-Hex: 2% (120 mL, 960 mL, 3840 mL); 4% (120 mL, 960 mL, 3840 mL)

Hibiclens®: 4% (15 mL, 120 mL, 240 mL, 480 mL, 960 mL, 3840 mL) [contains isopropyl alcohol]

Operand® Chlorhexidine Gluconate: 2% (120 mL); 4% (120 mL, 240 mL, 480 mL, 960 mL, 3840 mL) [contains isopropyl alcohol]

Liquid, oral rinse: 0.12% (480 mL)

Peridex®: 0.12% (480 mL) [contains alcohol 11.6%]

PerioGard®: 0.12% (480 mL) [contains alcohol 11.6%; mint flavor]

Liquid, topical: Hibistat®: 0.5% (240 mL, 480 mL) [contains isopropyl alcohol]

Pad [prep pad]: Hibistat®: 0.5% (50s) [contains isopropyl alcohol]

Sponge/Brush (BactoShield® CHG, Hibiclens®): 4% per sponge/brush [contains isopropyl alcohol]

International Brand Names:

Apo-Chlorhexadine® (CA); Hibidil® 1:2000 (CA); ORO-Clense (CA); SpectroGram 2™ (CA)

References

al-Tannir MA and Goodman HS, "A Review of Chlorhexidine and Its Use in Special Populations,"Spec Care Dentist, 1994, 14(3):116-22.

Emerson D and Pierce C, "A Case of a Single Ingestion of 4% Hibiclens®,"Vet Hum Toxicol, 1988, 30(6):583.

Ferretti GA, Brown AT, Raybould TP, et al, "Oral Antimicrobial Agents - Chlorhexidine,"NCI Monogr, 1990, 9:51-5.

Greenstein G, Berman C, and Jaffin R, "Chlorhexidine. An Adjunct to Periodontal Therapy,"J Periodontol, 1986, 57(6):370-7.

Johnson BT, "Uses of Chlorhexidine in Dentistry,"Gen Dent, 1995, 43(2):126-32, 134-40.

Massano G, Ciocatto E, Rosabianca C, et al, "Striking Aminotransferase Rise After Chlorhexidine Self-Poisoning,"Lancet, 1982, 1(8266):289.

Quinn MW and Bini RM, "Bradycardia Associated With Chlorhexidine Spray,"Arch Dis Child, 1989, 64(6):892-3.

Yong D, Parker FC, and Foran SM, "Severe Allergic Reactions and Intra-Urethral Chlorhexidine Gluconate,"Med J Aust, 1995, 162(5):257-8.

Yusof ZA, "Chlorhexidine Mouthwash: A Review of Its Pharmacological Activity, Clinical Effects, Uses and Abuses,"Dent J Malays, 1988, 10(1):9-16.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
adam.com